Investigation of the effect of empagliflozin on cardiac sympathetic and parasympathetic nerve activity in Japanese patients with type 2 diabetes

Not Applicable

• Conditions: Diabetes Mellitus (type 2)

• Registration Number: JPRN-UMIN000029194
• Lead Sponsor: Shinshu University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-09-19
• Study Completion: 2020-12-25
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 112

Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients treated with insulin or GLP-1 analogue 2) Patients with eGFR<45mL/min/1.73m2 3) Patients with Afib 4) Patients implanted PM 5) Patients who treated with beta-blockers, alpha-blokers, Digoxis, and CCB.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes from the baseline in LF, HF, and LF/HF ratio at the 24 weeks after the treatment. LF and HF will be estimated by heart rate valiability from 24-hour Holer ECG dataset, calcurated by spectral analysis.